Transarterial therapies for hepatocellular Carcinoma

Liver Cancer

Volumn 6, Issue 1, 2017, Pages 27-33

  Lanza, Ezio ^a   Donadon, Matteo ^a   Poretti, Dario ^a   Pedicini, Vittorio ^a   Tramarin, Marco ^a   Roncalli, Massimo ^a   Rheed, Hyungjin ^b   Park, Young Nyun ^c   Torzilli, Guido ^a  

^a HUMANITAS UNIVERSITY   (Italy)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Predictors of response after TAE and TACE for HCC; TAE and TACE for HCC

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD133 ANTIGEN; CD34 ANTIBODY; CORD BLOOD HEMATOPOIETIC STEM CELL EXTRACT; CYTOKERATIN 19; CYTOTOXIC AGENT; DOXORUBICIN; ELONGATION FACTOR 2 KINASE; EPITHELIAL CELL ADHESION MOLECULE; HEPATITIS B CORE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINATED POPPYSEED OIL; OCTAMER TRANSCRIPTION FACTOR 4; SORAFENIB; TRANSCRIPTION FACTOR NANOG; TWIST RELATED PROTEIN 1; VASCULOTROPIN; ZINC FINGER PROTEIN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL EMBOLIZATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRACHYTHERAPY; CELL DEATH; CHEMOEMBOLIZATION; CONFERENCE PAPER; DISEASE CONTROL; FATIGUE; FEVER; HUMAN; ILEUS; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; NAUSEA; PAIN; RADIOEMBOLIZATION; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR NECROSIS;

EID: 85022130669     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000449347     Document Type: Conference Paper

References (35)

1. European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943
2. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S, European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY): Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-878
3. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25
4. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401
5. Nakamura H, Hashimoto T, Oi H, Sawada S: Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-786
6. Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, Maeda M, Yoshioka T: Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1990;13:140-145
7. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K: Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83
8. Tsurusaki M, Murakami T: Surgical and locoregional therapy of HCC: TACE. Liver Cancer 2015;4:165-175
9. Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F: Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 2010;33:552-559
10. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006;17:217-223
11. Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, Crippin JS: Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005;16:1661-1666
12. Carr BI, Kondragunta V, Buch SC, Branch RA: Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-1314
13. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64
14. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C: Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-1837
15. Zhang Y, Li Y, Ji H, Zhao X, Lu H: Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends 2015;9:289-298
16. Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG: Hepatic radioembolization as a bridge to liver surgery. Front Oncol 2014;4:199
17. Teo JY, Allen JC Jr, Ng DC, Choo SP, Tai DW, Chang JP, Cheah FK, Chow PK, Goh BK: A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB Oxf 2016;18:7-12
18. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739
19. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171
20. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541-551
21. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M: The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261-2273
22. Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G: Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One 2015;10:e0133488
23. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim Y, Chau GY, Luca A, Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016;64:1090-1098
24. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M: Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015;7:2009-2019
25. Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V: TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int 2015;35:2466-2473
26. Huang GW, Yang LY, Lu WQ: Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol 2005;11:1705-1708
27. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002;20:1775-1785
28. Marie-Egyptienne DT, Lohse I, Hill RP: Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 2013;341:63-72
29. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J: High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010;59:953-962
30. Torbenson M, Schirmacher P: Liver cancer biopsy-back to the future?! Hepatology 2015;61:431-433
31. Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL: Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 2010;30:166-174
32. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732
33. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN: The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274-3284
34. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN: Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011;54:1707-1717
35. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA: Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 2011;71:3701-3708